| Code | CSB-RA007744MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to LKA-651, targeting the erythropoietin receptor (EPOR). EPOR is a type I cytokine receptor essential for red blood cell production, mediating the effects of erythropoietin (EPO) in erythropoiesis. Upon EPO binding, EPOR undergoes homodimerization and activates the JAK2-STAT5 signaling pathway, promoting survival, proliferation, and differentiation of erythroid progenitor cells. Dysregulation of EPOR signaling is implicated in various hematological disorders, including polycythemia vera, anemia associated with chronic diseases, and certain malignancies where aberrant EPOR expression may contribute to tumor progression and treatment resistance.
LKA-651 is a reference antibody used in investigating EPOR expression patterns and signaling mechanisms in both normal and pathological conditions. This biosimilar provides researchers with a reliable tool for studying erythropoiesis regulation, hematopoietic stem cell biology, and EPOR-mediated pathways in cancer research. It serves as a valuable reagent for examining receptor localization, expression levels, and functional studies in cellular and tissue-based experimental systems.
There are currently no reviews for this product.